Qsemble Capital Management’s Gilead Sciences GILD Stock Holding History

Qsemble Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.77M	Sell	37,783 -2,781	-7%	-$366K	0.61%	47
2026 Q1	$5.65M	Buy	+40,564	New	+$5.68M	0.43%	79
2025 Q4	–	Sell	-15,585	Closed	-$1.73M	–	530
2025 Q3	$1.73M	Buy	+15,585	New	+$1.77M	0.17%	179
2025 Q1	–	Sell	-15,616	Closed	-$1.44M	–	493
2024 Q4	$1.44M	Buy	+15,616	New	+$1.41M	0.19%	169
2024 Q3	–	Sell	-38,841	Closed	-$2.66M	–	443
2024 Q2	$2.66M	Sell	38,841 -1,555	-4%	-$104K	0.51%	58
2024 Q1	$2.96M	Buy	+40,396	New	+$3.11M	0.65%	28
2023 Q2	–	Sell	-12,900	Closed	-$1.07M	–	260
2023 Q1	$1.07M	Buy	12,900 +7,900	+158%	+$654K	0.72%	41
2022 Q4	$429K	Buy	+5,000	New	+$396K	0.3%	124

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qsemble Capital Management's GILD Position: Q2 2026 in Review

Qsemble Capital Management reduced its Gilead Sciences (GILD) stake by 6.9% in Q2 2026, selling an estimated $366K and leaving 37,783 shares worth $4.77M. The position accounts for 0.61% of the portfolio, ranked #47.

Qsemble Capital Management first reported a position in GILD in Q4 2022 and has held it in 8 quarters since. The position peaked at $5.65M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Qsemble Capital Management held 37,783 shares of Gilead Sciences worth $4.77M as of Q2 2026.
Qsemble Capital Management sold 2,781 Gilead Sciences shares in Q2 2026, an estimated $366K.
Gilead Sciences made up 0.61% of Qsemble Capital Management's portfolio in Q2 2026, its #47 holding.
Qsemble Capital Management first reported a position in Gilead Sciences in Q4 2022 and has held it in 8 quarters since.
Qsemble Capital Management's Gilead Sciences position peaked at $5.65M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.